BMO Capital Upgrades AbbVie To Outperform

BMO Capital upgraded

from Market Perform to Outperform. The price target for AbbVie has been raised from $60 to $68. AbbVie shares have surged 32.39% over the past 52 weeks, while the S&P 500 index has gained 14.83% in the same period. AbbVie shares rose 0.73% to $61.94 in pre-market trading.